As MZ1 mitigates the hook effect due to its positive cooperativity with respect to the assembly of ternary complexes [9], we decided to explore the combination of MZ1 and trastuzumab in preclinical models of HER2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.